Last reviewed · How we verify
VASOPRESSIN
Vasopressin is a marketed drug primarily indicated for the treatment of vasodilatory shock. Its key strength lies in its established mechanism and indication, providing a clear therapeutic option in critical care settings. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | VASOPRESSIN |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
- Vasodilatory Shock Treatment
Common side effects
- Decreased cardiac output
- Bradycardia
- Tachyarrhythmias
- Hyponatremia
- Ischemia (coronary)
- Ischemia (mesenteric)
- Ischemia (skin)
- Ischemia (digital)
Serious adverse events
- Hemorrhagic shock
- Myocardial ischemia
- Right heart failure
- Mesenteric ischemia
- Acute renal insufficiency
- Distal limb ischemia
- Intractable bleeding
- Atrial fibrillation
- Ischemic lesions
- Reversible diabetes insipidus
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial (PHASE2)
- Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
- Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome (NA)
- Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair (PHASE2)
- Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VASOPRESSIN CI brief — competitive landscape report
- VASOPRESSIN updates RSS · CI watch RSS